Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free TEVA Stock Alerts

Teva Pharmaceutical Industries (TEVA) Competitors

Teva Pharmaceutical Industries logo
$34.74 +0.31 (+0.89%)
Closing price 03:59 PM Eastern
Extended Trading
$34.76 +0.03 (+0.09%)
As of 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

TEVA vs. SNY, GSK, ARGX, TAK, and RVMD

Should you buy Teva Pharmaceutical Industries stock or one of its competitors? MarketBeat compares Teva Pharmaceutical Industries with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Teva Pharmaceutical Industries include Sanofi (SNY), GSK (GSK), argenex (ARGX), Takeda Pharmaceutical (TAK), and Revolution Medicines (RVMD).

How does Teva Pharmaceutical Industries compare to Sanofi?

Sanofi (NASDAQ:SNY) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Sanofi has a net margin of 8.66% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Sanofi's return on equity.

Company Net Margins Return on Equity Return on Assets
Sanofi8.66% 14.19% 7.95%
Teva Pharmaceutical Industries 4.08%32.64%6.34%

Sanofi presently has a consensus target price of $49.50, suggesting a potential upside of 15.71%. Teva Pharmaceutical Industries has a consensus target price of $42.00, suggesting a potential upside of 20.92%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Sanofi.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sanofi
1 Sell rating(s)
9 Hold rating(s)
3 Buy rating(s)
2 Strong Buy rating(s)
2.40
Teva Pharmaceutical Industries
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90

In the previous week, Teva Pharmaceutical Industries had 4 more articles in the media than Sanofi. MarketBeat recorded 30 mentions for Teva Pharmaceutical Industries and 26 mentions for Sanofi. Sanofi's average media sentiment score of 1.09 beat Teva Pharmaceutical Industries' score of 0.88 indicating that Sanofi is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sanofi
12 Very Positive mention(s)
4 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Teva Pharmaceutical Industries
23 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Sanofi has higher revenue and earnings than Teva Pharmaceutical Industries. Sanofi is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sanofi$49.35B2.10$8.84B$1.9122.40
Teva Pharmaceutical Industries$17.26B2.31$1.41B$0.6057.89

Sanofi has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

Summary

Teva Pharmaceutical Industries beats Sanofi on 9 of the 17 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to GSK?

Teva Pharmaceutical Industries (NYSE:TEVA) and GSK (NYSE:GSK) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

In the previous week, Teva Pharmaceutical Industries had 23 more articles in the media than GSK. MarketBeat recorded 30 mentions for Teva Pharmaceutical Industries and 7 mentions for GSK. Teva Pharmaceutical Industries' average media sentiment score of 0.88 beat GSK's score of 0.56 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
23 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
GSK
3 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Teva Pharmaceutical Industries presently has a consensus target price of $42.00, indicating a potential upside of 20.92%. GSK has a consensus target price of $53.00, indicating a potential upside of 2.82%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, research analysts clearly believe Teva Pharmaceutical Industries is more favorable than GSK.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90
GSK
2 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.10

GSK has a net margin of 14.56% compared to Teva Pharmaceutical Industries' net margin of 4.08%. GSK's return on equity of 43.23% beat Teva Pharmaceutical Industries' return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries4.08% 32.64% 6.34%
GSK 14.56%43.23%11.60%

Teva Pharmaceutical Industries has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, GSK has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market.

GSK has higher revenue and earnings than Teva Pharmaceutical Industries. GSK is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$17.26B2.31$1.41B$0.6057.89
GSK$43.07B2.42$7.54B$3.2016.11

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 10.0% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

GSK beats Teva Pharmaceutical Industries on 9 of the 17 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to argenex?

Teva Pharmaceutical Industries (NYSE:TEVA) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Teva Pharmaceutical Industries has higher revenue and earnings than argenex. argenex is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$17.26B2.31$1.41B$0.6057.89
argenex$4.25B12.78$1.29B$26.0433.33

argenex has a net margin of 32.19% compared to Teva Pharmaceutical Industries' net margin of 4.08%. argenex's return on equity of 43.59% beat Teva Pharmaceutical Industries' return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries4.08% 32.64% 6.34%
argenex 32.19%43.59%36.66%

Teva Pharmaceutical Industries has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, argenex has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market.

Teva Pharmaceutical Industries currently has a consensus price target of $42.00, suggesting a potential upside of 20.92%. argenex has a consensus price target of $1,056.89, suggesting a potential upside of 21.77%. Given argenex's stronger consensus rating and higher probable upside, analysts clearly believe argenex is more favorable than Teva Pharmaceutical Industries.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90
argenex
0 Sell rating(s)
4 Hold rating(s)
18 Buy rating(s)
2 Strong Buy rating(s)
2.92

In the previous week, Teva Pharmaceutical Industries had 15 more articles in the media than argenex. MarketBeat recorded 30 mentions for Teva Pharmaceutical Industries and 15 mentions for argenex. argenex's average media sentiment score of 0.94 beat Teva Pharmaceutical Industries' score of 0.88 indicating that argenex is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
23 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
argenex
8 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 2.4% of argenex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

argenex beats Teva Pharmaceutical Industries on 12 of the 17 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

In the previous week, Teva Pharmaceutical Industries had 17 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 30 mentions for Teva Pharmaceutical Industries and 13 mentions for Takeda Pharmaceutical. Teva Pharmaceutical Industries' average media sentiment score of 0.88 beat Takeda Pharmaceutical's score of 0.57 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Takeda Pharmaceutical
6 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Teva Pharmaceutical Industries
23 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Takeda Pharmaceutical has a beta of -0.08, suggesting that its share price is 108% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

Teva Pharmaceutical Industries has a consensus target price of $42.00, suggesting a potential upside of 20.92%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Takeda Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Takeda Pharmaceutical
2 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00
Teva Pharmaceutical Industries
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90

Teva Pharmaceutical Industries has lower revenue, but higher earnings than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Takeda Pharmaceutical$28.32B1.89-$1.01B$0.3449.17
Teva Pharmaceutical Industries$17.26B2.31$1.41B$0.6057.89

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Teva Pharmaceutical Industries has a net margin of 4.08% compared to Takeda Pharmaceutical's net margin of 3.80%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Takeda Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Takeda Pharmaceutical3.80% 10.95% 5.34%
Teva Pharmaceutical Industries 4.08%32.64%6.34%

Summary

Teva Pharmaceutical Industries beats Takeda Pharmaceutical on 15 of the 16 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to Revolution Medicines?

Teva Pharmaceutical Industries (NYSE:TEVA) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Teva Pharmaceutical Industries currently has a consensus target price of $42.00, suggesting a potential upside of 20.92%. Revolution Medicines has a consensus target price of $144.67, suggesting a potential downside of 26.67%. Given Teva Pharmaceutical Industries' higher possible upside, equities research analysts clearly believe Teva Pharmaceutical Industries is more favorable than Revolution Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90
Revolution Medicines
1 Sell rating(s)
1 Hold rating(s)
18 Buy rating(s)
2 Strong Buy rating(s)
2.95

Teva Pharmaceutical Industries has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market.

In the previous week, Teva Pharmaceutical Industries had 7 more articles in the media than Revolution Medicines. MarketBeat recorded 30 mentions for Teva Pharmaceutical Industries and 23 mentions for Revolution Medicines. Teva Pharmaceutical Industries' average media sentiment score of 0.88 beat Revolution Medicines' score of 0.87 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
23 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Revolution Medicines
16 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

Teva Pharmaceutical Industries has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$17.26B2.31$1.41B$0.6057.89
Revolution Medicines$11.58M3,622.28-$1.13B-$7.07N/A

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Teva Pharmaceutical Industries has a net margin of 4.08% compared to Revolution Medicines' net margin of 0.00%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Revolution Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries4.08% 32.64% 6.34%
Revolution Medicines N/A -83.22%-59.06%

Summary

Teva Pharmaceutical Industries beats Revolution Medicines on 10 of the 17 factors compared between the two stocks.

Get Teva Pharmaceutical Industries News Delivered to You Automatically

Sign up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TEVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TEVA vs. The Competition

Export
MetricTeva Pharmaceutical IndustriesPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$39.59B$11.54B$6.87B$24.09B
Dividend YieldN/A2.73%2.60%3.70%
P/E Ratio57.89788.92280.3432.26
Price / Sales2.31735.83600.2120.44
Price / Cash9.2372.4271.7932.38
Price / Book5.1510.8512.976.92
Net Income$1.41B$2.82B$3.49B$1.07B
7 Day Performance0.54%3.34%3.57%2.63%
1 Month Performance0.52%-1.90%-2.50%1.55%
1 Year Performance120.96%193.72%73.94%19.52%

Teva Pharmaceutical Industries Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TEVA
Teva Pharmaceutical Industries
4.264 of 5 stars		$34.74
+0.9%		$42.00
+20.9%		+119.2%$39.59B$17.26B57.8933,950
SNY
Sanofi
3.5759 of 5 stars		$44.00
+1.5%		$49.50
+12.5%		-11.2%$105.10B$49.35B12.2974,846
GSK
GSK
2.7234 of 5 stars		$51.97
+1.2%		$53.00
+2.0%		+37.0%$103.87B$43.07B13.5066,841
ARGX
argenex
4.4932 of 5 stars		$888.82
-3.2%		$1,054.11
+18.6%		+22.3%$57.44B$4.25B34.131,863
TAK
Takeda Pharmaceutical
1.9299 of 5 stars		$17.45
+1.2%		N/A+16.2%$55.24B$28.32B44.7547,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:TEVA) was last updated on 8/5/2026 by MarketBeat.com Staff.
From Our Partners
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
What's the Best Way to Lower RMD Taxes?
Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...
SmartAsset | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
“The unseen winner of the AI race” is not SpaceX
Marc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...
Chaikin Analytics | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
BlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?
BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...
Awesomely | Sponsoredtc pixel